-
OncoTargets and Therapy
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
The ubiquitin–proteasome system as a molecular target in solid tumors: an update on bortezomib
Review
(2596) Views (710) Full article downloads
Authors: A Milano, F Perri, F Caponigro
Published Date June 2009
Volume 2009:2 Pages 171 - 178
DOI: http://dx.doi.org/10.2147/OTT.S4503
A Milano,1 F Perri,2 F Caponigro2
1Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy; 2Head and Neck Medical Oncology Unit, National Tumour institute of Naples, Naples, Italy
Abstract: The ubiquitin–proteasome system has become a promising molecular target in cancer therapy due to its critical role in cellular protein degradation, interaction with cell cycle and apoptosis regulation, and unique mechanism of action. Bortezomib (PS-341) is a potent and specific reversible proteasome inhibitor, which has shown strong in vitro antitumor activity as single agent and in combination with other cytotoxic drugs in a broad spectrum of hematological and solid malignancies. In preclinical studies, bortezomib induced apoptosis of malignant cells through the inhibition of NF-κB and stabilization of pro-apoptotic proteins. Bortezomib also promotes chemo- and radiosensitization of malignant cells in vitro and inhibits tumor growth in murine xenograft models. The proteasome has been established as a relevant target in hematologic malignancies and bortezomib has been approved for the treatment of multiple myeloma. This review summarizes recent data from clinical trials in solid tumors.
Keywords: proteasome, bortezomib, NF-κB, clinical studies, solid tumors
Other articles by Dr Francesco Caponigro
Readers of this article also read:
Management of glucocorticoids-induced osteoporosis: role of teriparatide
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Multiple roles and therapeutic implications of Akt signaling in cancer
Coenzyme Q10 effects in neurodegenerative disease
Antibiotic treatment of exacerbations of COPD in general practice: long-term impact on healthrelated quality of life
The dual kinase complex FAK-Src as a promising therapeutic target in cancer
An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease
Development and implementation of treadmill exercise testing protocols in COPD
Phenotype characterization of embryoid body structures generated by a crystal comet effect tail in an intercellular cancer collision scenario
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Intranet access to all Dove journals
If you would like your institutional intranet to have access to the Dove Medical Press journals please contact me.
- Epigenomics in cancer management
- Intercellular cancer collisions generate an ejected crystal comet tail effect with fractal interface embryoid body reassembly transformation
- Topotecan in the treatment of relapsed small cell lung cancer
- Role of trabectedin in the treatment of soft tissue sarcoma




